【益佰制药是哪个国家的品牌？】

贵州益佰制药股份有限公司是一家集新型药品的研究、开发、生产和销售为一体的高新技术企业。公司创建于1995年6月12日，2000年11月完成股份制改造，并于2004年3月在上海证券交易所成功上市(证券代码600594)，成为贵州省首家取得上市资格的非公有制企业。

公司占地面积134398平方米，建有符合国家药品生产质量管理规范(简称GMP)的生产厂房43200平方米。目前拥有省内生产基地3个，省外生产基地4个。现有小针剂、冻干粉针、大输液等49个品规产品，9条注射剂生产线。配备有国际先进水平的尖端生产设备。

截止至2012年12月，公司工业产值近30亿元，销售收入近28亿元(集团合并数据)，2012年贵州省内纳税3.86亿元，公司成立至今累计向国家纳税已超过23亿元。2013年1-6月，公司工业产值已达11.6亿元，纳税1.82亿，销售收入同比去年增长率稳定在15%左右。

公司在发展过程中一直致力于完善公司治理，不断提高公司治理水平。公司制定了规范的《公司章程》、“三会”议事规则，实施了独立董事制度，设置了战略发展委员会、审计委员会、提名委员会和薪酬与考核委员会，制定了严格规范的财务制度和信息披露制度，形成了一套权责明确、权力制衡的管理机制，为公司的持续、健康发展提供了制度保证。

公司现有员工4000余人，其中大专以上学历人员占总人数的81%。公司本着“百年树人”的理念，始终给予员工培训工作极大的重视，对员工采取多种形式进行培训，通过学习培训，有效地提高了全体员工的工作积极性，使员工的整体素质得到了全面的提升。公司高级管理人员送往清华大学、中欧国际工商学院、国研斯坦福、长江管理学院、上海交通大学等国家重点院校进行管理学习，并在公司内部举办总经理培训班，聘知名专家上课，挑选公司管理人员及部分优秀员工参加，旨在提高管理人员的综合素质。公司还将专业技术人员送往相关药学院进行专业培训，注重提高公司技术实力和培养创新精神;坚持工人培训制度，不断加强工人文化素质、修养、技术技能的提高，全公司员工严格按每年300个以上学时进行相应培训。这些举措为公司配备良好的管理队伍、技术队伍和其他后备人才提供了有力保证，也为企业的可持续发展奠定了坚实的基础。

公司目前的主要产品有克咳家族系列、艾迪注射液、银杏达莫注射液、注射用洛铂、复方斑蝥胶囊、理气活血滴丸、前列癃闭通颗粒等众多优势品种。在这些已形成企业优势系列产品中，复方中药针剂艾迪注射液和复方斑蝥胶囊为双相抗肿瘤新药，其中艾迪注射液的研究已达到基因水平;第四代银杏制剂----银杏达莫注射液，是心、脑血管及外周循环障碍的有效治疗药物，它的面世为广大的心脑血管病患者带来了福音;注射用洛铂是国家一类新药，第三代铂类抗肿瘤药物，相对其他铂类，其毒性较低、耐药性较小。理气活血滴丸则是独家原研苗药，是治疗心血管疾病的一线用药，具有极大的市场潜力。

公司在产品研发上大力投入，并得到了政府各级部门的认可，2006年获批为第十三批“国家认定企业技术中心”，2006年获批为博士后工作站，2007年获批为“贵州省新型释药系统药物工程技术研究中心”，2008年被评为国家级创新型试点企业，2008年建成益佰制药新药研发中试基地，2009年被评为国家地方联合工程研究中心，2009年发改委授予“西南民族药新型制剂工程研究中心”，2012年发改委授予”西南地区(贵州)药品生产动员中心”、2012年科技部授予“国家级创新型企业”。

正是基于企业的综合实力，益佰制药连续七年荣登中国制药工业百强榜和2012年度中国最具竞争力医药上市公司20强。

一直以来，公司十分重视知识产权的保护工作，2004年就成立了专门的知识产权部门，并采取了申请专利保护及创建驰名商标等措施，注重发展核心技术，提升企业自主创新能力。截止至2012年末，公司的专利申请量和商标申请量居省内同行业第一名，居国内同行业领先地位。其中，公司申请了发明专利199件，授权115件;申请外观专利82件，授权76件。完成临床前研究及注册申报94项，实施临床研究7项，获得生产批文共计27件。

目前，公司已经牵头组建了苗药集团，同时还与北京中药大学联合拟招收了第一批苗药专业研究生。在壮大企业自身的同时，为苗药的发展创造条件，为贵州药业的发展做出贡献。

公司在全国主要城市建立了良好的营销网络，配备了训练有素的销售队伍，实现企业从产品到患者服务全过程的质量跟踪服务。

公司为促进医药产业结构优化，提高产品集中度，本着加速并购，自主创新的发展理念，在过去几年陆续收购了桂林漓江制药、云南南诏药业、贵州民族药业、海南长安制药等生产型制药企业，这些企业的品种已有很好的市场销售，并具有非常广阔的市场前景。2012年，益佰再次加速自己整合并购的步伐，收购北京爱德药业有限公司80%的股份，将基因工程药品的开发、生产、销售一举融入到益佰的医药健康产业链之中。

作为贵州省医药行业龙头企业，依托贵州省提出的《贵州省十大工业产业振兴规划》和我市提出的“5+1”工业体系，实施“千亿产业百亿企业”计划，为促进我省社会经济发展，投资20亿建设益佰工业园，该项目于2012年初正式动工。益佰工业园位于贵阳市金阳新区与云岩区交界处，占地面积600余亩，总建筑面积423648㎡,总投资194036.49万元，一期工程建设以注射剂车间为主，现已完成3万余平方米的主体工程建设及相关设备调试，其中提取车间土建和安装工作已完成，进入工艺设备管道安装阶段;制剂车间土建工作已完成，现进入工艺设备调试阶段;设备进入试运行调试阶段;将于2013年6月30日之前报送国家食药总局申请新版GMP认证。一旦通过验证，就可以保证企业转型升级和药品市场规范的同步发展。

益佰始终投身公益事业，在2008年初的凝冻灾害中益佰第一时间向灾区人民发出慰问，并捐赠60万元，支援灾区;2008年5月四川汶川地震灾害中，我们冲锋在前，向灾区受难的同胞捐赠了现金共计124万和价值100万的药品;在2010年初的贵州干旱灾情中，捐赠现金280万元;并在多个国家级贫困县捐资助学。公司董事长兼总裁窦啟玲女士在国家级贫困县——赫章县建立希望小学。截止至2012年，益佰已累计向社会捐助善款物资超过1000万元。

公司以“卓越的医药产品提供者，优秀的健康医疗服务领航者”为使命，在经济市场大潮中，恪守着“健康100、品质100、感恩100、创新100”的价值观，为客户提供优质高效符合环保要求的产品，为投资者创造最大的财富，为社会创造最大的价值。向“成为中国医药产业受尊敬的，具有持续经营潜力的公司”愿景不断迈进。

英文翻译：Guizhou Yibai Pharmaceutical Co., Ltd. is a high-tech enterprise integrating research, development, production and sales of new drugs. The company was founded on June 12, 1995, completed the share-holding transformation in November 2000, and successfully listed on the Shanghai Stock Exchange in March 2004 (securities code: 600594), becoming the first non-public enterprise in Guizhou Province to obtain the listing qualification. The company covers an area of 134398 square meters, and has built 43200 square meters of production plant in line with the GMP. At present, it has 3 production bases in the province and 4 production bases outside the province. There are 49 products and 9 injection production lines including small injection, freeze-dried powder injection and large infusion. Equipped with international advanced level of cutting-edge production equipment. As of December 2012, the company's industrial output value is nearly 3 billion yuan, sales revenue is nearly 2.8 billion yuan (group consolidated data). In 2012, Guizhou province paid taxes of 386 million yuan, and the company has paid taxes to the state more than 2.3 billion yuan since its establishment. From January to June 2013, the industrial output value of the company has reached 1.16 billion yuan, and the tax payment is 182 million yuan. The growth rate of sales revenue is stable at about 15% year on year. In the process of development, the company has been committed to improving corporate governance and constantly improving the level of corporate governance. The company has formulated standardized articles of association and rules of procedure of the "three meetings", implemented independent director system, set up strategic development committee, audit committee, nomination committee and remuneration and assessment committee, formulated strict and standardized financial system and information disclosure system, and formed a set of management mechanism with clear rights and responsibilities and power checks and balances for the company's sustainable and healthy development Exhibition provides system guarantee. The company has more than 4000 employees, including 81% of them with college degree or above. In line with the concept of "one hundred years to cultivate people", the company has always attached great importance to the training of employees, and has taken various forms of training for employees. Through learning and training, the enthusiasm of all employees has been effectively improved, and the overall quality of employees has been comprehensively improved. Senior managers of the company are sent to Tsinghua University, China Europe International Business School, national research Stanford, Yangtze River Management College, Shanghai Jiaotong University and other national key universities for management study, and general manager training courses are held within the company, famous experts are invited to attend classes, and management personnel and some excellent employees of the company are selected to participate, in order to improve the comprehensive quality of management personnel. The company also sent professional and technical personnel to relevant pharmaceutical colleges for professional training, focusing on improving the company's technical strength and cultivating the spirit of innovation; adhere to the workers' training system, and constantly strengthen the improvement of workers' cultural quality, cultivation and technical skills, and the company's employees receive corresponding training in strict accordance with more than 300 class hours per year. These measures provide a strong guarantee for the company to be equipped with good management team, technical team and other reserve talents, and also lay a solid foundation for the sustainable development of the enterprise. At present, the company's main products include Keke family series, Aidi injection, gingko Damo injection, lobaplatin for injection, compound cantharis capsule, Liqihuoxue dropping pill, qianliehuangaotong granules and many other superior varieties. Among these products, Aidi injection and cantharis capsule are two-phase anti-tumor drugs, among which the research of Aidi injection has reached the level of gene; The fourth generation of Ginkgo biloba preparation, Ginkgo biloba Damo injection, is an effective drug for the treatment of cardiovascular, cerebrovascular and peripheral circulatory disorders. Its appearance has brought good news to the vast number of patients with cardiovascular and cerebrovascular diseases. Lotplatin for injection is a new drug in China. The third generation of platinum antitumor drugs, compared with other platinum drugs, has lower toxicity and less drug resistance. Liqihuoxue dropping pill is the exclusive original vaccine drug, which is the first-line drug for the treatment of cardiovascular diseases and has great market potential. The company has invested heavily in product research and development, and has been recognized by government departments at all levels. In 2006, it was approved as the 13th batch of "national recognized enterprise technology center", in 2006, it was approved as postdoctoral workstation, in 2007, it was approved as "Guizhou new drug release system drug engineering technology research center", in 2008, it was rated as a national innovative pilot enterprise, and in 2008, it was built into Yibai pharmaceutical new drug center In 2009, the R & D pilot base was awarded as the national and local joint engineering research center, the "southwest national medicine new preparation engineering research center" by the national development and Reform Commission, the "southwest region (Guizhou) drug production mobilization center" by the national development and Reform Commission in 2012, and the "national innovative enterprise" by the Ministry of science and technology in 2012. Based on the comprehensive strength of the enterprise, Yibai pharmaceutical has been listed in the top 100 pharmaceutical companies in China for seven consecutive years and the top 20 most competitive pharmaceutical listed companies in China in 2012. The company has always attached great importance to the protection of intellectual property. In 2004, it established a special intellectual property department, and took measures such as applying for patent protection and creating well-known trademarks, focusing on the development of core technology and improving the independent innovation ability of enterprises. By the end of 2012, the number of patent applications and trademark applications of the company ranked first in the same industry in the province, ranking the leading position in the same industry in China. Among them, the company has applied for 199 invention patents and authorized 115; applied for 82 appearance patents and authorized 76. 94 pre clinical studies and registration applications were completed, 7 clinical studies were carried out, and 27 production approvals were obtained. At present, the company has taken the lead in setting up Miao medicine group, and at the same time, it plans to recruit the first batch of Miao medicine graduate students jointly with Beijing University of traditional Chinese medicine. At the same time of strengthening the enterprise itself, it creates conditions for the development of Miao medicine and makes contributions to the development of Guizhou medicine industry. The company has established a good marketing network in the major cities of the country, equipped with a well-trained sales team, and realized the quality tracking service of the whole process from product to patient service. In order to promote the optimization of the pharmaceutical industry structure and improve the product concentration, in line with the development concept of accelerating M & A and independent innovation, the company has successively acquired such production-oriented pharmaceutical enterprises as Guilin Lijiang pharmaceutical, Yunnan Nanzhao pharmaceutical, Guizhou national pharmaceutical and Hainan Chang'an pharmaceutical in the past few years. The varieties of these enterprises have good market sales and have a very broad market prospect. In 2012, Yibai once again accelerated its pace of integration and acquisition, acquired 80% of the shares of Beijing ed Pharmaceutical Co., Ltd., and integrated the development, production and sales of genetically engineered drugs into Yibai's pharmaceutical and health industry chain. As a leading enterprise in Guizhou pharmaceutical industry, relying on the "ten industrial revitalization plan of Guizhou Province" and the "5 + 1" industrial system proposed by our city, we have implemented the "100 billion industrial enterprises" plan. In order to promote the social and economic development of our province, we have invested 2 billion to build Yibai Industrial Park, which was officially started in early 2012. Yibai Industrial Park is located at the junction of Jinyang New District and Yunyan District, Guiyang City, covering an area of more than 600 mu, with a total construction area of 423648 ㎡, a total investment of 1940364900 yuan. The injection workshop is the main part of the first phase of the project, and the main project construction and related equipment commissioning of more than 30000 square meters have been completed, among which the civil engineering and installation work of the extraction workshop has been completed, and the process equipment pipeline installation stage has entered; The civil work of the preparation workshop has been completed, and now it is in the stage of process equipment commissioning; the equipment is in the stage of trial operation commissioning; it will be submitted to the State Food and Drug Administration for new GMP certification before June 30, 2013. Once verified, it can ensure the synchronous development of enterprise transformation and upgrading and drug market norms. Yibai has always been engaged in public welfare undertakings. In the freezing disaster in early 2008, Yibai first sent condolences to the people in the disaster area and donated 600000 yuan to support the disaster area. In the Wenchuan earthquake in May 2008, we rushed ahead and donated 1.24 million yuan in cash and 1 million yuan worth of drugs to the victims in the disaster area. In the drought disaster in Guizhou in early 2010, we donated 2.8 million yuan in cash; And in a number of state-level poverty-stricken counties to donate money. Ms. Dou Qiling, chairman and President of the company, established hope primary school in Hezhang County, a national poverty-stricken county. Up to 2012, Yibai has donated more than 10 million yuan to the society. With the mission of "excellent medical product provider and excellent health care service leader", the company adheres to the values of "Health 100, quality 100, gratitude 100 and innovation 100" in the economic market tide, provides customers with high-quality and efficient products that meet the requirements of environmental protection, creates the greatest wealth for investors and creates the greatest value for the society. To "become a respected and sustainable company in China's pharmaceutical industry" vision.

本文链接： https://www.waitui.com/brand/e55c88407.html 联系电话：0851-84705590